Quantcast
Viewing all articles
Browse latest Browse all 193599

Russell Investments Group Ltd. Raises Stake in Masimo Co. (NASDAQ:MASI)

Image may be NSFW.
Clik here to view.
Masimo logo
Russell Investments Group Ltd. raised its stake in Masimo Co. (NASDAQ:MASI) by 5.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,652 shares of the medical equipment provider’s stock after buying an additional 1,555 shares during the quarter. Russell Investments Group Ltd.’s holdings in Masimo were worth $7,037,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Swiss National Bank lifted its stake in shares of Masimo by 16.6% in the 4th quarter. Swiss National Bank now owns 233,289 shares of the medical equipment provider’s stock valued at $62,610,000 after purchasing an additional 33,189 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in Masimo during the 4th quarter worth about $3,211,000. Illinois Municipal Retirement Fund lifted its stake in Masimo by 243.9% during the 4th quarter. Illinois Municipal Retirement Fund now owns 25,945 shares of the medical equipment provider’s stock worth $6,963,000 after acquiring an additional 18,401 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Masimo during the 4th quarter worth about $2,331,000. Finally, JPMorgan Chase & Co. lifted its stake in Masimo by 27.4% during the 4th quarter. JPMorgan Chase & Co. now owns 138,556 shares of the medical equipment provider’s stock worth $37,185,000 after acquiring an additional 29,789 shares in the last quarter. Institutional investors own 80.99% of the company’s stock.

A number of equities research analysts have issued reports on MASI shares. Piper Sandler reduced their price target on Masimo from $310.00 to $295.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 24th. Robert W. Baird reaffirmed a “buy” rating and issued a $310.00 price target on shares of Masimo in a research report on Thursday, April 29th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Masimo presently has a consensus rating of “Buy” and a consensus price target of $284.80.

MASI opened at $224.59 on Wednesday. Masimo Co. has a one year low of $203.81 and a one year high of $284.86. The stock has a market cap of $12.35 billion, a P/E ratio of 57.00 and a beta of 0.75. The firm has a 50-day simple moving average of $225.08.

Masimo (NASDAQ:MASI) last released its quarterly earnings results on Sunday, April 25th. The medical equipment provider reported $0.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.02. The firm had revenue of $299.04 million for the quarter, compared to the consensus estimate of $296.22 million. Masimo had a return on equity of 14.95% and a net margin of 19.54%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.97 EPS. On average, research analysts expect that Masimo Co. will post 3.83 earnings per share for the current fiscal year.

In related news, CFO Micah W. Young sold 2,087 shares of the firm’s stock in a transaction that occurred on Thursday, April 8th. The stock was sold at an average price of $239.00, for a total transaction of $498,793.00. Following the transaction, the chief financial officer now owns 16,680 shares in the company, valued at approximately $3,986,520. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 9.10% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Read More: 52 Week Highs

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASI).

Image may be NSFW.
Clik here to view.
Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)


Viewing all articles
Browse latest Browse all 193599

Trending Articles